IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34⁺ progenitor-derived NK cells.

ABSTRACT: Allogeneic natural killer (NK) cell transfer is a potential immunotherapy to eliminate and control cancer. A promising source are CD34 + hematopoietic progenitor cells (HPCs), since large numbers of cytotoxic NK cells can be generated. Effective boosting of NK cell function can be achieved by interleukin (IL)-15. However, its in vivo half-life is short and potent trans-presentation by IL-15 receptor α (IL-15Rα) is absent. Therefore, ImmunityBio developed IL-15 superagonist N-803, which combines IL-15 with an activating mutation, an IL-15Rα sushi domain for trans-presentation, and IgG1-Fc for increased half-life. Here, we investigated whether and how N-803 improves HPC-NK cell functionality in leukemia and ovarian cancer (OC) models in vitro and in vivo in OC-bearing immunodeficient mice. W

SUBMITTER: Van der Meer JMR 

PROVIDER: S-EPMC8053152 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature